Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 18/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143627 | 0.94 | IDH1 (0.50) | IDH1KDM4EAPAF1LMNAMAPT | |
| SCHEMBL31127320 | 0.93 | IDH1 (0.61) | IDH1 | |
| SCHEMBL21143606 | 0.93 | IDH1 (0.61) | IDH1 | |
| Rimtuzalcap SCHEMBL19686931 | 0.87 | IDH1 (0.43) | IDH1KDM4EAPAF1LMNAMAPT | |
| Rimtuzalcap SCHEMBL29920754 | 0.87 | IDH1 (0.43) | IDH1KDM4EAPAF1LMNAMAPT | |
| SCHEMBL19687055 | 0.86 | IDH1 (0.44) | IDH1KDM4EAPAF1LMNAMAPT | |
| SCHEMBL19687044 | 0.85 | IDH1 (0.43) | IDH1KDM4EAPAF1LMNAMAPT | |
| SCHEMBL19687051 | 0.85 | IDH1 (0.43) | IDH1KDM4EAPAF1LMNAMAPT | |
| SCHEMBL19687442 | 0.85 | IDH1 (0.41) | IDH1KDM4EAPAF1LMNAMAPT | |
| SCHEMBL19686707 | 0.85 | IDH1 (0.41) | IDH1KDM4EAPAF1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885KDM4E 1648/4885APAF1 3655/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885KDM4E 1648/4885APAF1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.